Fig. 3

Plasma CXCL9, CXCL10 and CXCL11 levels during PHI are correlated with CD4⁺ T-cell counts. a Analysis of correlations between plasma CXCL9 (r = − 0.051, p = 0.7195), CXCL10 (r = − 0.1013, p = 0.4751), and CXCL11 (r = -0.0357, p = 0.8014) levels at the HIV⁺ point and CD4⁺ T-cell count at the same sampling point (n = 52). b Comparisons of CXCL9, CXCL10, and CXCL11 levels between the CD4⁺-high (n = 16) and CD4⁺-low (n = 36) groups at the sampling point (CXCL9, p = 0.9448; CXCL10, p = 0.7407; CXCL11, p = 0.9893). c Analysis of the correlations between plasma CXCL9 (r = − 0.3062, p = 0.0737), CXCL10 (r = − 0.2059, p = 0.2354), and CXCL11 (r = − 0.2406, p = 0.1638) levels at the HIV⁺ point and CD4⁺ T-cell count at set-point (n = 35). d Comparisons of CXCL9, CXCL10, and CXCL11 levels between the CD4⁺-high (n = 16) and CD4⁺-low (n = 19) groups at set-point (CXCL9, p = 0.1662; CXCL10, p = 0.5256; CXCL11, p = 0.3317). e Analysis of the correlations between plasma CXCL9 (r = − 0.5692, p = 0.0007), CXCL10 (r = -0.1952, p = 0.2843), and CXCL11 (r = − 0.3741, p = 0.0349) levels at the HIV⁺ point and CD4⁺ T-cell count at 1-year-infection (n = 32). f Comparisons of CXCL9, CXCL10, and CXCL11 levels between the CD4⁺-high (n = 10) and CD4⁺-low (n = 22) groups at 1-year-infection (CXCL9, p = 0.0008; CXCL10, p = 0.0242; CXCL11, p = 0.0106)